Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Frechen – page 40

1 443 clinical trials in Frechen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Frechen at a glance
1 443
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 443 trials in Frechen

Open in trial search

Nephroblastoma

Recruiting

Study Comparing Vincristine, Actinomycin-D, and Doxorubicin with Vincristine, Carboplatin, and Etoposide for Stage IV Childhood Kidney Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Study of Nivolumab for Patients with Metastatic Solid Tumors and Leptomeningeal Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Glioblastoma

Recruiting

Study of Meclofenamate Sodium and Temozolomide for Patients with Progressive MGMT-Methylated Glioblastoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Meclofenamate Sodium
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Study on Pelacarsen for Slowing Calcific Aortic Valve Stenosis in Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Study Comparing Methylprednisolone Aceponate Creams and a Non-Active Cream for Patients with Mild to Moderate Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Methylprednisolone Aceponate
  • Sponsor:Dermapharm AG

Long-term Safety Study of Exagamglogene Autotemcel for Patients with Sickle Cell Disease or Transfusion-Dependent Thalassemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Exagamglogene Autotemcel
  • Sponsor:Vertex Pharmaceuticals Inc.

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MK-1084
  • Sponsor:Merck Sharp & Dohme LLC

Comparison of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Myelofibrosis+1

Recruiting

Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International

Study on the Effect of Guselkumab for Treating Enthesitis in Patients with Psoriatic Arthritis Who Have Not Used Biologic DMARDs

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Universitaetsklinikum Erlangen AöR

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Frechen

What the registry says about research in the country

01 Hematologic Oncology

Clinical research focusing on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), evaluating new combination therapies with venetoclax and comparing different treatment durations based on measurable residual disease.

  • Treatment Duration Optimization
  • Combination Therapy Assessment
  • Disease Progression Monitoring

Innovative approaches in blood cancer treatment aimed at improving patient outcomes through personalized therapy duration.

02 Supportive Cancer Care

Investigation into preventing and managing chemotherapy-induced polyneuropathy (CIPN) using Aconite Pain Oil, with a focus on improving quality of life for cancer patients undergoing chemotherapy treatment.

  • Neuropathy Prevention
  • Symptom Management
  • Quality of Life Enhancement

Novel approaches to reducing chemotherapy side effects and maintaining treatment effectiveness.

03 Precision Medicine

Advanced research incorporating artificial intelligence to evaluate treatment resistance in patients with polycythemia vera, focusing on predicting hydroxyurea resistance patterns.

  • AI-Based Prediction Models
  • Treatment Resistance Analysis
  • Personalized Treatment Strategies

Integration of machine learning with clinical practice to optimize treatment selection and patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.